The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2013-10-31
Target enrollment:
Participant gender:
Summary
High-dose interleukin 2 (Proleukin, Novartis) (IL-2) is approved by the U.S Food and Drug
Administration (FDA) for the treatment of metastatic kidney cancer and is a standard
treatment of this disease. At the present time, IL-2 is the only therapy for kidney cancer
that can produce a remission of disease that lasts after treatment is completed. However,
most patients who receive IL-2 do not benefit and all patients experience potentially
dangerous side effects.
Recent research has suggested that certain patients may respond better to IL-2 than others.
The Cytokine Working Group is currently conducting a clinical trial that aims to identify and
confirm this research and narrow the application of IL-2 to those patients most likely to
benefit.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
City of Hope National Medical Center Dartmouth-Hitchcock Medical Center Indiana University Loyola University Our Lady of Mercy Medical Center Providence Cancer Center, Earle A. Chiles Research Institute Roswell Park Cancer Institute University of California, Los Angeles University of Cincinnati University of Pittsburgh University of Virginia Vanderbilt University Vanderbilt University Medical Center Wayne State University